The 9th meeting of the 8th board of supervisors of Joincare Pharmaceutical Group Industry Co.Ltd(600380) Pharmaceutical Group
Stock Code: Joincare Pharmaceutical Group Industry Co.Ltd(600380) securities abbreviation: Joincare Pharmaceutical Group Industry Co.Ltd(600380) Announcement No.: pro 2022045 Joincare Pharmaceutical Group Industry Co.Ltd(600380)
Announcement of resolutions of the 9th meeting of the 8th board of supervisors
The board of supervisors and all supervisors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents The 9th meeting of the 8th board of supervisors of Joincare Pharmaceutical Group Industry Co.Ltd(600380) (hereinafter referred to as “the company”) was notified by e-mail and confirmed by telephone on Friday, April 15, 2022, and was held in the form of on-site and video conference in room 2, building of Joincare Pharmaceutical Group Industry Co.Ltd(600380) Pharmaceutical Group after the 10th meeting of the 8th board of directors of the company on Friday, April 22, 2022. The meeting was convened and presided over by Mr. Yu Xiaoyun, chairman of the board of supervisors. Three supervisors should attend the meeting and three supervisors actually attended the meeting. The meeting was held in accordance with the provisions of the company law and the articles of association. The following proposals were considered and adopted at this meeting:
1、 Deliberated and passed the proposal on nominating Mr. Xing Zhiwei as a candidate for supervisor of the board of supervisors
Since Mr. Xie Zhiwei has been nominated by the shareholders of the company to be the supervisor of the company until the expiration of the term of office of the eighth session of the board of supervisors due to the provisions of the articles of association of the company, Mr. Xie Xingwei has resigned as the supervisor of the company. Mr. Xie Youguo will continue to perform the duties of supervisor of the company until the new supervisor is re elected by the general meeting of shareholders of the company.
After verification, the board of supervisors of the company believes that the qualifications of the above candidates for supervisors meet the relevant provisions of the company law and the articles of association, and there is no situation that they are not allowed to serve as supervisors of the company according to the provisions of the company law and the articles of Association, and there are no other circumstances that Shanghai stock exchange determines that they are not suitable to serve as supervisors of listed companies. Voting result: 3 affirmative votes; No negative vote; There were no abstentions.
This proposal needs to be submitted to the general meeting of shareholders of the company for deliberation.
2、 Deliberated and adopted opinions on Joincare Pharmaceutical Group Industry Co.Ltd(600380) 2022 first quarter report
The preparation and review procedures of the company’s 2022 first quarter report comply with relevant laws and regulations, the articles of association and various provisions of the company’s internal management system, and the content and format of the first quarter report comply with China’s requirements
The 9th meeting of the 8th board of supervisors of Joincare Pharmaceutical Group Industry Co.Ltd(600380) Pharmaceutical Group
The information contained in the provisions of the CSRC and Shanghai stock exchange can truly and completely reflect the operation, management and financial status of the company in the first quarter of 2022 in all aspects, and the personnel participating in the preparation and deliberation of the first quarter report have not violated the confidentiality provisions.
Voting result: 3 affirmative votes; No negative vote; There were no abstentions.
3、 Deliberated and passed the proposal on the company’s second phase of shareholding plan for medium and long term business partners (Draft) and its summary
Upon review, the board of supervisors of the company believes that:
1. The company’s second phase shareholding plan (Draft) of medium and long term business partner shareholding plan (hereinafter referred to as the plan) and its abstract comply with the company law, the securities law, the guiding opinions on the pilot implementation of employee stock ownership plan by listed companies (hereinafter referred to as the Guiding Opinions), the guidelines for self discipline supervision of listed companies on Shanghai Stock Exchange No. 1 – standardized operation and other relevant laws, administrative regulations Regulations, normative documents and relevant provisions of the articles of association do not prohibit the implementation of the ESOP as stipulated in the guiding opinions and other relevant laws, administrative regulations, rules and normative documents.
2. There is no situation that employees are forced to participate in the plan by means of apportionment or forced distribution, nor is there any plan or arrangement for the company to provide loans, loan guarantees or any other financial assistance to the holders of the plan.
3. The implementation of this plan will not harm the interests of the company and all shareholders and meet the needs of the company’s long-term development. 4. The implementation of this plan by the company will help to realize the company’s development concept and effectively stimulate the entrepreneurial spirit of the company’s senior managers. By giving rights and obligations to the holders and establishing a partnership mechanism of “benefit sharing and risk sharing” for business partners, the company will effectively promote and promote the transformation of the company’s “manager” to “partner” identity, and gather a group of era fighters and business leaders with common values, Carry forward entrepreneurship, realize the sustainable development of the company and ensure the achievement of the company’s development goals.
5. Before the implementation of the plan, the company has fully solicited the opinions of employees through the employee congress, and the relevant review procedures and decisions are legal and effective.
Voting result: 3 affirmative votes; No negative vote; There were no abstentions.
It is hereby announced.
Joincare Pharmaceutical Group Industry Co.Ltd(600380) April 25, 2002
